Cargando…

Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells

While treatment for B-cell malignancies has been revolutionized through the advent of CAR immunotherapy, similar strategies for T-cell malignancies have been limited. Additionally, T-cell leukemias and lymphomas can commonly metastasize to the CNS, where outcomes are poor and treatment options are a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Jia, Xu, Haichan, Cinquina, Andrew, Wu, Zehua, Chen, Qi, Zhang, Ping, Wang, Xingen, Shan, Huiming, Xu, Lei, Zhang, Qian, Sun, Lihua, Zhang, Wenli, Pinz, Kevin G., Wada, Masayuki, Jiang, Xun, Hanes, William M, Ma, Yupo, Zhang, Hongyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8036178/ https://www.ncbi.nlm.nih.gov/pubmed/33410096 http://dx.doi.org/10.1007/s12015-020-10092-9

Ejemplares similares

Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells
por: Feng, Jia, et al.
Publicado: (2022)

Treatment of Systemic Lupus Erythematosus using BCMA-CD19 Compound CAR
por: Zhang, Wenli, et al.
Publicado: (2021)

Preclinical Targeting of Human Acute Myeloid Leukemia Using CD4-specific Chimeric Antigen Receptor (CAR) T Cells and NK Cells
por: Salman, Huda, et al.
Publicado: (2019)

Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies
por: Chen, Kevin H., et al.
Publicado: (2016)

Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells
por: Pinz, Kevin G., et al.
Publicado: (2017)

Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia
por: Petrov, Jessica C., et al.
Publicado: (2018)

Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia
por: Myers, G Doug, et al.
Publicado: (2021)

Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells
por: Wei, Zhenyu, et al.
Publicado: (2023)

CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia
por: Saleh, Khalil, et al.
Publicado: (2023)

Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT
por: Wei, Jia, et al.
Publicado: (2022)

S116: DONOR-DERIVED CD5 CAR T CELLS FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: Pan, Jing, et al.
Publicado: (2023)

Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia
por: Tan, Yue, et al.
Publicado: (2023)

Prognostic relevance of genetic variations in T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma
por: Yu, Hui, et al.
Publicado: (2019)

CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity
por: Shi, Jiangzhou, et al.
Publicado: (2021)

Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments
por: Xu, Xinjie, et al.
Publicado: (2021)

Cardiac involvement in a patient with B-cell lymphoblastic lymphoma/acute lymphoblastic leukemia and a history of allogeneic hematopoietic stem cell transplantation and CAR T-cell therapy: A case report
por: Cao, Yigeng, et al.
Publicado: (2023)

Low LEF1 expression is a biomarker of early T-cell precursor, an aggressive subtype of T-cell lymphoblastic leukemia
por: Wang, Mei, et al.
Publicado: (2020)

CAR T-Cells in Acute Lymphoblastic Leukemia: Current Status and Future Prospects
por: Almaeen, Abdulrahman H., et al.
Publicado: (2023)

Radiation therapy improves CAR T cell activity in acute lymphoblastic leukemia
por: Sugita, Mayumi, et al.
Publicado: (2023)

Anti-CD19 CAR T-cell consolidation therapy combined with CD19(+) feeding T cells and TKI for Ph(+) acute lymphoblastic leukemia
por: Chen, Li-Yun, et al.
Publicado: (2023)

CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome
por: Chen, Liting, et al.
Publicado: (2020)

Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies
por: Xu, Xinjie, et al.
Publicado: (2019)

P353: NATURALLY SELECTED CD7-TARGETED CAR-T CELL THERAPY FOR RELAPSED OR REFRACTORY CENTRAL NERVOUS SYSTEM T-CELL LYMPHOBLASTIC LEUKEMIA/LYMPHOMA
por: Yang, Junfang, et al.
Publicado: (2023)

Identification of methylation signatures associated with CAR T cell in B-cell acute lymphoblastic leukemia and non-hodgkin’s lymphoma
por: Song, Jiwei, et al.
Publicado: (2022)

Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells
por: Wang, Hongxia, et al.
Publicado: (2021)

CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report
por: Sun, Yao, et al.
Publicado: (2021)

Effects of CAR-T Cell Therapy on Immune Cells and Related Toxic Side Effect Analysis in Patients with Refractory Acute Lymphoblastic Leukemia
por: Li, Lianlian, et al.
Publicado: (2023)

Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study
por: Yang, Junfang, et al.
Publicado: (2022)

Predictors of response to axicabtagene‐ciloleucel CAR T cells in aggressive B cell lymphomas: A real‐world study
por: Iovino, Lorenzo, et al.
Publicado: (2022)

The place of allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma in the era of CAR-T-cell therapy
por: Castagna, Luca, et al.
Publicado: (2022)

Genomic landscape of T-cell lymphoblastic lymphoma
por: Li, Zhaoming, et al.
Publicado: (2022)

PB2499: BLINATUMOMAB SEQUENTIAL ANTI-CD22 CAR-T CELLS AND HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SUCCESSFUL TREATMENT OF B LYMPHOBLASTIC LEUKEMIA EXTRAMEDULLARY RECURRENCE: A CASE REPORT
por: Yao, Hao, et al.
Publicado: (2023)

Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia
por: Liu, Shuangyou, et al.
Publicado: (2020)

Integrating CAR T-Cell Therapy and Transplantation: Comparisons of Safety and Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation After CAR T-Cell or Chemotherapy-Based Complete Remission in B-Cell Acute Lymphoblastic Leukemia
por: Zhao, Yan-Li, et al.
Publicado: (2021)

Efficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia
por: Zhao, Xiangyu, et al.
Publicado: (2020)

Engineering CAR-T cells
por: Zhang, Cheng, et al.
Publicado: (2017)

Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatment
por: Teipel, Raphael, et al.
Publicado: (2022)

CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies
por: Zhang, Li-Na, et al.
Publicado: (2018)

A case of B-cell lymphoblastic leukemia cutis flaring following CAR T-cell therapy in a patient with refractory acute lymphoblastic leukemia
por: Puri, Pranav, et al.
Publicado: (2020)

A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia
por: Martino, Massimo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_keret347h1cti9jisvocf8t1au